CHRONIC MYELOID LEUKIMIA 3
Chronicmyeloid leukemia which is also referred to as chronic leukemia is along-term illness of the bone marrow. People that have this conditionnormally have a defect that causes one part of the chromosome tobreak off and then it attaches itself to a different chromosome. Thisleads to a chromosome that is short, and it is known as Philadelphiachromosome.
Theexchange of genetic information leads to the formation of two geneswhich are BCR and ABL, which then join to form one gene referred toas BCR-ABL.The BCR-ABL gene makes the bone produce an enzyme that isabnormal. This enzyme arouses the white blood cells which then growout of control making increases in the count of white blood cells aswell as the size of the spleen in one`s body (Hsu, Lee & Wang,2008).
Someof the advances doctors have made in regard to treatment of chronicmyelogenous leukemia is that there are various treatment options forthis chronic disease that are as follows: The control of the diseasewith oral tyrosine kinase inhibitors such as Tasigna. The otheroption is the possible cure with bone marrow transplantations. Thisis mainly after the ailment does not respond to the treatment withtyrosine kinase inhibitors (TKI).
Chemotherapyis also an option of treatment that reduces the symptoms of thesickness. Therapy is chosen depending on the stage of CML, whetherthere is a presence of a stem donor, the patients’ candidacy forstem cell transplantation and also the inclination of the patient.Some of the advances that the doctors have also made are that theprimary objective of treatment is to get rid of the Philadelphiachromosome that is abnormal. When the treatment is effective, theblood counts go back to normal. The hematologic response is used tomeasure the extent of the reaction (Malek, 2013).
Hsu,W., Lee, M. L., & Wang, J. (2008). Temporaland spatio-temporal data mining.Hershey: IGI Pub.
InMalek, S. (2013). Advancesin chronic lymphocytic leukemia.